Saks Global Weighs Chapter 11 Bankruptcy Amid Debt Pressures and Luxury Retail Slowdown 
BP Nears $10 Billion Castrol Stake Sale to Stonepeak 
Sanofi to Acquire Dynavax in $2.2 Billion Deal to Strengthen Vaccines Portfolio 
Warner Bros. Discovery Shares Slide Amid Report of Potential Paramount Skydance Lawsuit 
ByteDance Plans Massive AI Investment in 2026 to Close Gap With U.S. Tech Giants 
California DMV Proposes New Safety Rules for Autonomous Vehicles After Waymo Incidents 
South Korean Court Clears Korea Zinc’s $7.4 Billion U.S. Smelter Project, Shares Surge 
Novo Nordisk Stock Surges After FDA Approves Wegovy Pill for Weight Loss 
GLP-1 Weight Loss Pills Set to Reshape Food and Fast-Food Industry in 2025 
Hyundai Recalls Over 51,000 Vehicles in the U.S. Due to Fire Risk From Trailer Wiring Issue 
Waymo Plans Safety and Emergency Response Upgrades After San Francisco Robotaxi Disruptions 
Hanwha Signals Readiness to Build Nuclear-Powered Submarines at Philly Shipyard for U.S. Navy 
TSMC Honors Japanese Chip Equipment Makers With 2025 Supplier Awards 
Nvidia and Groq Strike Strategic AI Inference Licensing Deal 
Nike Stock Jumps After Apple CEO Tim Cook Buys $2.9M Worth of Shares 
Eli Lilly and Novo Nordisk Battle for India’s Fast-Growing Obesity Drug Market 
SANTA MONICA, Calif., Feb. 16, 2016 -- Kite Pharma, Inc., (Nasdaq:KITE) today announced that David D. Chang, M.D., Ph.D., Executive Vice President, Research and Development, and Chief Medical Officer, will participate in a fireside chat discussion at the 2016 RBC Capital Markets Global Healthcare Conference.
| Event: | 2016 RBC Capital Markets Global Healthcare Conference | |
| Date: | Tuesday, February 23, 2016 | |
| Time: | 4:05 PM Eastern Time | |
| Location: | New York, NY | |
A live audio webcast will be available on the Investors section of Kite’s website, www.kitepharma.com. A replay of the webcast will be available on the website for approximately 30 days.
About Kite Pharma
Kite Pharma, Inc., is a clinical-stage biopharmaceutical company engaged in the development of novel cancer immunotherapy products, with a primary focus on engineered autologous cell therapy (eACT™) designed to restore the immune system's ability to recognize and eradicate tumors. Kite is based in Santa Monica, CA. For more information on Kite Pharma, please visit www.kitepharma.com. Sign up to follow @KitePharma on Twitter at www.twitter.com/kitepharma.
CONTACT: Greg Mann VP, Investor Relations [email protected] For Media: Justin Jackson Burns McClellan (212) 213-0006 [email protected]
